A SINGLE DOSE, COMPARATIVE BIOAVAILABILITY STUDY OF EPINEPHRINE NASAL SPRAY AND EPINEPHRINE INTRAMUSCULAR INJECTION IN ALLERGEN-CHALLENGED SUBJECTS UNDER FASTING CONDITIONS

Registry ID

2024-5657

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

HIKMA PHARMACEUTICALS USA INC

Completion date

2025-05-21

Last update

2024-11-08

Conditions

• ALLERGIES

Related clinical trials

• AN OPEN-LABEL, MULTI-CENTER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED REMIBRUTINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH REMIBRUTINIB
• A PHASE 1B, OPEN-LABEL, EXPLORATORY STUDY EVALUATING THE EFFECTS OF INHALED EPINEPHRINE IN INDIVIDUALS EXPERIENCING SYSTEMIC ALLERGIC REACTIONS DURING ALLERGY TESTING, IMMUNOTHERAPY OR ORAL CHALLENGES
• PREMED-F1: FEASIBILITY OF A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE USE OF CETIRIZINE AS A REPLACEMENT FOR DYPHENHYDRAMINE TO PREVENT REACTIONS LINKED TO PACLITAXEL PERFUSION

View on source registry